Objective: This study aimed to describe self-reported patterns of use and effects of lysergic acid diethylamide (LSD) analogues (AL-LAD, 1P-LSD, and ETH-LAD) and the characteristics of those who use them.
| INTRODUCTION
Since the first use of lysergic acid diethylamide (LSD) in 1943 by Albert Hofmann (Hofmann, 1980) , many similarly structured compounds have emerged such as ALD-52, AL-LAD (or Aladdin), ETH-LAD, PRO-LAD, LSZ, and 1P-LSD, to name just a few (Brandt et al., 2017; Brandt et al., 2016; Peyton & Shulgin, 1994; Watts, Mailman, Lawler, Neve, & Nichols, 1995) . The increased speed emergence of these new psychoactive substances (NPS) is partially driven by legislative processes chasing a synthesise-proscribe-synthesise model (Reuter & Pardo, 2017) . For example, 1P-LSD use increased in popularity in the UK following prohibition of LSZ and AL-LAD in 2015 (Brandt et al., 2016) . Since May 2016, the UK Psychoactive Substances Act prohibited the supply of 1P-LSD and any other compounds deemed to cause a "psychoactive effect" (Reuter & Pardo, 2017) . Other countries now have similar blanket bans on all "psychoactive" substances (such as Ireland, Poland, Romania, and Australia; see Barratt, Seear, & Lancaster, 2017) or on analogues of psychoactive substances (United States; see Kau, 2008) . Although the effectiveness of these policies is yet to be fully established, they may result in a shift in purchase from "head shops" or high street shops to surface web vendors, cryptomarkets, and into "street" markets (as discussed in Barratt & Lenton, 2017; Reuter & Pardo, 2017) . The use of LSD analogues including 1P-LSD has been recently reported amongst nightclub attendees in the United States (Palamar, Acosta, Sherman, Ompad, & Cleland, 2016) , and social media and cryptomarket monitoring studies have also recently detected discussion of this class of drugs (Van Hout & Hearne, 2017; Vigna et al., 2016) .
LSD analogues and LSD share the same lysergic backbone.
However, they present slight variations in their chemical structure, such as AL-LAD's modification at the N6 position (Brandt et al., 2017) . These lysergide derivatives act as an agonist of the 5-HT2A receptor (Brandt et al., 2016) , generally considered the mediator of hallucinogenic effects behaviourally and subjectively (Geyer & Vollenweider, 2008) . There are ethical barriers associated with the administration of hallucinogens to humans for research purposes:
There is an unknown potential for harm associated with this class of drugs, and the subjectivity of individuals' responses can vary significantly. Therefore, animal behavioural models are useful for investigating the pharmacology of these drugs. Hallucinogenic effects can be illustrated by measuring the head twitch response in mice (Hanks & Gonzalez-Maeso, 2013) . The head twitch response in mice is a side-to-side head movement elicited only by a hallucinogenic 5-HT2A agonist, which effectively discriminates between hallucinogenic and non-hallucinogenic 5-HT2A agonists. This response was found for mice that had been administered 1P-LSD (Brandt et al., 2016) , indicating that 1P-LSD is indeed likely to have hallucinogenic effects in humans. Although lab-based evidence for human experience of 1P-LSD does not exist, detailed experiences reported by users (see Psychonaut Wiki, 2016a) include auditory and visual perceptual alterations following the consumption of 1P-LSD.
Research on mice regarding the potency of these compounds compared to LSD (ED50 = 132.8 nmol/kg) indicated 1P-LSD (ED50 = 349.6 nmol/kg) to be 38% the potency of LSD (Brandt et al., 2016) , AL-LAD slightly less potent (ED50 = 174.9 nmol/kg), and LSZ equipotent (ED50 = 114.2 nmol/kg; Brandt et al., 2017) . These varying potencies shown in mice do not reflect reported dosages in humans.
The typical dosage of LSD is approximately 150 μg, however, the dosage of AL-LAD ranged between 80 and 160 μg (Shulgin & Shulgin, 1997) , LSZ between 100 and 300 μg (Erowid, 2014) , and 1P-LSD between 50 and 300 μg (Psychonaut Wiki, 2016a) . The duration of the effects of LSD analogues (AL-LAD and LSZ 6-10 hr and 1P-LSD 8-12 hr; Psychonaut Wiki, 2016a Wiki, , 2016b Wiki, , 2016c ) is, however, comparable to that of typical LSD (6-12 hr).
What we currently know about the use of LSD analogues in humans is based on animal models plus the experience and effect reports posted to websites and wikis. In this paper, we use an anonymous web survey to describe the self-reported effect profile of LSD analogues, including AL-LAD, 1P-LSD, and ETH-LAD, in humans, in comparison to the effect profile of the better-known drug, LSD.
We also compare LSD analogue and LSD user profiles.
| METHOD
An anonymous online survey on the use of psychoactive substances was designed and conducted by Global Drug Survey (GDS) (http:// www.globaldrugsurvey.com/archive/GDS2016/) between November 2015 and February 2016. GDS runs the world's biggest drug survey and is conducted annually, in partnership with global media partners who promote the survey to their audiences. In 2016, the survey was translated into 10 languages. GDS enables rapid assessment and identification of novel drugs as well as new drug trends before their spread to the wider community (e.g., Kaar et al., 2016; Lawn, Barratt, Williams, Horne, & Winstock, 2014; Lawn, Borschmann, Cottrell, & Winstock, 2016) . Ethical approval was received from King's College London (PNM1415-18). Participation was voluntary, and no incentives (payments or lotteries) were offered for participation.
A total of 100,711 responses were submitted to GDS. After preparing the data, 3,817 records were excluded due to data capture glitches, duplicate entries, reporting no psychoactive drug use at all, reporting the use of a fake drug, and reported age over 100 years.
Almost one third of the remaining 96,894 responses were from Germany (n = 29,865, 31%), followed by Switzerland (n = 8,173, 8%), New Zealand (n = 7,633, 8%), UK (n = 6,015, 6%), United States (n = 5,366, 6%), Netherlands (n = 5,058, 5%), and Australia (n = 4,931, 5%), with the remaining countries accounting for 31%.
The average age of respondents was 28.7 years (SD = 11.2, range = 16-95), and the majority were male (64%) with the remaining female (34%), and transgender (1%). The subsample comprised 3,678 respondents who reported LSD analogues or LSD as their last new drug tried. The average age of the subsample was 23.4 years (SD = 5.7, range = 16-56), and the majority were male (74%) with the remaining female (25%), and transgender (1%).
Self-reported lifetime use and recent (last 12 month) use of LSD and LSD analogues were collected. The use of LSD analogues was measured separately for AL-LAD and also as a category, labelled "LSD Analogues (e.g., 1P-LSD and ETH-LAD)." For this paper, variables relating to AL-LAD and LSD Analogues (e.g., 1P-LSD and ETH-LAD) were combined and hereon referred to as "LSD analogues."
Although it is possible that respondents may have included others, the three LSD analogues named in the survey were AL-LAD, 1P-LSD, and ETH-LAD. For both LSD and LSD analogues, profiling information was collected regarding route of administration (ROA), source of the drug, and effects such as the type of effect, duration, time to peak, strength (scored from 1 to 10, 10 = extremely strong), pleasurable high (scored from 1 to 10, 10 = best ever had), comedown (scored from 1 to 10, 10 = extremely strong), urge to use more drugs (scored from 1 to 10, 10 = extremely strong), negative effects whilst high (scored from 1 to 10, 10 = extremely strong), risk of harm following use of the drug (scored from 1 to 10, 10 = extremely high risk), and value for money (scored from 1 to 10, 10 = best experienced), where these drugs were identified as being the last drug tried for the first time. This profiling set of variables has been used previously by the GDS group to profile NPS, including mephedrone (Winstock et al., 2011) , the NBOMe series (Lawn et al., 2014) , DMT (Winstock, Kaar, & Borschmann, 2014) , and methoxetamine (Winstock, Lawn, Deluca, & Borschmann, 2016) .
Prior to running the multivariate analyses, missing value analysis on variables of interest showed no variables with less than 5% missing.
Multicollinearity and singularity were also tested using a Pearson product moment correlation. All variables correlated in a meaningful way, ensuring the validity of the statistical analysis used (Tabachnick & Fidell, 2013) . Normality and homoscedasticity assumptions for multivariate analyses were met. Linearity appeared to be violated; however, multivariate analysis of variance (MANOVA) is robust to this violation (Tabachnick & Fidell, 2013) , and therefore, conducting a MANOVA was deemed acceptable. As described more fully in the results, the univariate assumption of equality of variance was not met for some variables. MANOVA was conducted to compare differences between LSD and LSD analogues on effects such as strength, pleasurable high, negative effects whilst high, comedown, risk of harm following use, and value for money. Independent samples t tests were conducted to determine differences in duration and time to peak. The alpha level was set at .05 and only valid percentages were used. Table 1 ). Recent (last 12-month) LSD use was reported by 13% of the entire sample (n = 12,491), whereas recent LSD analogue use was reported by 1% (n = 1,431). Of the 2,202 respondents with available data who reported ever using LSD analogues, 2,004 (91%) reported lifetime use of LSD. Of the 1,249 with available data who reported using LSD analogues in the last 12 months, 1,055 (85%) also reported LSD use in the last 12 months.
| Demographics of LSD analogue users
Comparisons of demographic characteristics were performed between individuals who reported (a) use of LSD analogues in the last 12 months and (b) use of LSD in the last 12 months but not LSD analogues (see Table 2 ). There was a significantly higher proportion of recent LSD analogue users in the UK and the United States compared with recent LSD users. Overall, recent LSD analogue users had a younger mean age and were more likely to be male compared with recent LSD users.
3.3 | Description by those whom an LSD analogue was "the last new drug tried" Almost all participants reporting LSD analogues as their last new drug tried described the effects as mostly psychedelic (LSD/ketamine like; 93%), whereas 2% described it as mostly stimulant (cocaine/amphetamine like), 1% mostly cannabis like, and 1% mostly empathogenic (MDMA/ecstasy like). Additionally 2% of the group described the effects as "other." The most common source of LSD analogues was online (n = 186, 56%), followed by a friend (n = 111, 33%), then a dealer (n = 28, 8%); these reported sources were significantly different from the ones reported for LSD, χ(5) = 649.20, p < .001, which was less likely to be sourced online (n = 260, 8%) and more likely to be sourced from a Note. GDS = Global Drug Survey; LSD = lysergic acid diethylamide.
a LSD analogue group included respondents who reported use of LSD analogues in the last 12 months, and the LSD group included respondents who reported use of LSD in the last 12 months but not LSD analogues.
b Results from the top seven countries in the whole GDS sample are reported here.
friend (n = 2,251, 68%). The majority of participants reported swallowing as the common ROA (n = 278, 83%) whereas the 17% of other ROA commonly reported "sublingual," "blotter," and "tab," which are all oral routes. Only one participant reported snorting and one other reported injecting. Reported ROA for LSD did not significantly differ from LSD analogues ROA, χ(5) = 7.69, p = .174.
| Comparison of effects of LSD and LSD analogues
The modal duration of effect for both LSD and LSD analogues was 8 hr. The results indicated no significant difference in duration between LSD and LSD analogue groups, t(443) = 1.50, p = .134. The modal time to peak was 2 hr for both LSD and LSD analogues. There were no significant difference in mean times to peak for LSD and LSD analogues, t(3601) = .85, p = .398.
A MANOVA was conducted to compare LSD (n = 3,015) and LSD analogues (n = 306) on pleasurable high, strength of effect, negative effects whilst high, comedown, urge to use more, value for money, and risk of harm following use of the drug. The assumption of equality of variance was not met for pleasurable high, F(1, 3319) = 7.37, Table 3 ).
| DISCUSSION
To our knowledge, this paper is the first to describe patterns of use and self-reported effects of LSD analogues (AL-LAD, 1P-LSD, and ETH-LAD) in humans. In this sample, "typical" users of these analogues were males aged in their mid-20s, identifying as "White," who were mostly full-time students or employed. These characteristics were similar to the demographics of other psychedelic drug users (e.g., Lawn et al., 2014; Winstock et al., 2014) , although they may also reflect the bias of people inclined to complete the GDS. Nonetheless, some differences were identified between LSD and LSD analogue users. There were significantly higher proportions of respondents from the UK and the United States reporting recent LSD analogue use compared to recent LSD only use. It should be noted that these survey data were collected during a period when 1P-LSD was still legal in the UK, therefore this trend may be subject to change in future years. The majority of participants who had used LSD analogues reported that they had obtained LSD analogues online, which significantly differed from methods used to obtain LSD, matching with previous reports on the widespread availability of NPS online (Brandt, King, & Evans-Brown, 2014; Van Buskirk, Naicker, Roxburgh, Bruno, & Burns, 2016) . The most common ROA was oral, and the majority of participants reported the type of effect as psychedelic (LSD/ketamine like), which did not significantly differ from LSD. The modal duration of effect reported for LSD analogues (8 hr) as well as the time to peak (2 hr) was the same as LSD. A comparison of the reports on perceived effects of LSD analogues and LSD showed that LSD was rated significantly higher for pleasurable high, strength, urge to use more drugs, value for money, risk of harm following use, and comedown. These results suggest that LSD analogues are "weaker"
versions of LSD. This result is consistent with animal research showing LSD analogues such as 1P-LSD having a lower potency than LSD in mice (Brandt et al., 2016) .
This study has several limitations. The main weakness of this study was the possible drug reporting inaccuracies, both intentional and unintentional as well as manufacturer mislabelling. It is possible that users led to believe they were taking LSD were in fact consuming one of its analogues and vice versa. Also, it is plausible that the substances taken were unrelated to LSD such as those from the NBOMe series (Caldicott, Bright, & Barratt, 2013; Martins et al., 2017 under review) . Future studies should seek to replicate these findings with chemical confirmation. In addition, future studies should investigate harms of LSD analogues, both short term and long term. Measuring additional detail regarding the experience such as dosage and whether or not other drugs were consumed concurrently should be considered to gain a better understanding of LSD analogue effects in humans. A further limitation is that the survey sample was self-selected, and therefore, not necessarily representative of a wider population of psychedelic users.
| CONCLUSION
This is the first study to describe the self-reported effect profile of LSD analogues, including AL-LAD, 1P-LSD, and ETH-LAD, in humans. The profile of LSD analogues was reported to be very similar to LSD in Note. Effect ratings were on a scale of 1 (lowest) to 10 (highest). LSD = lysergic acid diethylamide; MANOVA = multivariate analysis of variance.
relation to duration, time to peak, and ROA (oral). However, LSD analogues were considered weaker in regard to strength, pleasurable high, and comedown. Future research should monitor and test the substances subject to investigation and seek to replicate and confirm these initial findings.
